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 Introduction 
 Acute kidney injury (AKI) is a devastating clinical 
condition associated with high levels of morbidity and 
mortality despite best supportive care and lacks any spe-
cific interventions to improve outcome. The majority of 
cases of AKI do not arise from primary renal disease but 
rather as a result of systemic insults such as dehydration, 
surgery or sepsis leading to renal hypoperfusion. If renal 
perfusion is not immediately restored, then ischaemia-
reperfusion injury (IRI) can occur in the kidney leading 
to acute tubular necrosis (ATN) and functional derange-
ment in the form of AKI. Research using experimental 
animal models has led to an increasing appreciation that 
the eventual injury phenotype is determined by a balance 
between intrinsic and extrinsic factors promoting cellu-
lar function and survival, and the deleterious effects of 
circulatory dysfunction and immune activation within 
the kidney.
 The Biological Role of Hemeoxygenase-1 
 Hemeoxygenases are the enzymes responsible for the 
catalysis of heme molecules in mammalian cells. They 
play a vital biological role in the response to cellular in-
jury, which can result in the denaturing of heme-contain-
ing compounds. These free heme molecules act as a po-
tent source of secondary oxidative stress if not promptly 
metabolized. 
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 Abstract 
 Degradation by the inducible enzyme hemeoxygenase-1 
(HO-1) is the principal route of mammalian heme metabo-
lism. The resultant generation of free iron, carbon monoxide 
and biliverdin results in myriad actions including promoting 
cell survival, circulatory integrity and immunomodulation. 
This review examines the evidence from both human studies 
and work performed in experimental models implicating 
the intrinsic heme-HO-1 pathway as important in determin-
ing both the susceptibility and severity of acute kidney in-
jury. Additional work using chemical inducers of HO-1 has 
demonstrated the efficacy of strategies to upregulate en-
zyme activity in ameliorating the severity of experimental 
ischaemia-reperfusion injury whilst genetic ablation of HO-1 
or pharmacological inhibition of HO-1 activity results in an 
augmented injury phenotype. There remain a multitude of 
candidate pathways to account for the therapeutic efficacy 
of HO-1 induction. Although this may reflect a truly multifac-
torial mechanism of action, the identification of the relative 
contribution of key components such as carbon monoxide 
generation remains critical to allow the rational design of 
agents for translational application in human disease. 
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 Whilst the constitutively expressed enzymes hemeoxy-
genase-2 and -3 contribute a basal level of heme metabo-
lism, the predominant route of heme degradation is via 
inducible hemeoxygenase-1 (HO-1). In addition to remov-
ing a source of oxidative stress, 2 products of heme me-
tabolism, biliverdin and carbon monoxide (CO), are rec-
ognized to possess immunomodulatory, anti-apo ptotic 
and in the case of CO, vasoactive properties  [1] ( fig. 1 ). 
HO-1 induction is also coupled to the increased availabil-
ity of ferritin, leading to prompt conjugation and removal 
of free iron – another source of potential oxidative stress.
 As such, HO-1 may modulate the behaviour of the im-
mune system and the function of the microcirculation, all 
of which may ameliorate IRI. Accordingly, both the role 
of HO-1 in the renal response to IRI and its potential ther-
apeutic manipulation are the subject of ongoing research.
 HO-1 and the Kidney 
 Our current knowledge of the role of HO-1 in renal 
disease is largely based on experience of animal models of 
kidney disease, with additional insights from limited 
studies performed in human renal biopsy material. Heme 
molecules are generated ubiquitously by all nucleated cells 
in the body including those of the kidney, resulting in the 
need for a similarly widespread availability of HO-1 for 
heme metabolism. Both experimental models and human 
biopsy material have demonstrated that HO-1 is expressed 
at low levels within the healthy kidney. Also, human data 
suggest that HO-1 is a component of the tubulointerstitial 
response to injury, with tubular induction of HO-1 cor-
relating with reduced markers of oxidative stress  [2] . 
These findings are consistent with the single reported case 
of human HO-1 deficiency, which was characterized by 
systemic inflammation, haemolysis and a nephropathy 
with progressive tubulointerstitial inflammation  [3] . 
 The kidney can be subject to additional heme loads 
after tissue injury via the circulation – with experimental 
models demonstrating the key role for HO-1 in the suc-
cessful metabolism of otherwise cytotoxic quantities of 
myoglobin after induction of rhabdomyolysis  [4] . Consis-
tent with this, the HO-1 –/– mouse demonstrates exagger-
ated iron accumulation in the kidney under physiologic 
conditions with heightened susceptibility to AKI follow-
ing models of IRI, rhabdomyolysis and cisplatin-induced 
AKI  [5–7] .
 HO-1 and Renal IRI 
 HO-1 is induced in a range of organs including the ro-
dent kidney in response to experimental IRI  [8] . Further-
more, data from pre- and post-implantation biopsies of 
human renal allografts demonstrate HO-1 induction in 
post-implantation specimens, with the maximal HO-1 
induction evident in allografts exhibiting delayed graft 
function  [9] . Renal HO-1 expression can be induced by 
diverse noxious stimuli including hypoxia, lipopolysac-
charide administration and bile duct ligation, all of which 
result in protection against a subsequent, more severe ex-
perimental IRI insult; this implicates HO-1 induction as 
a potential mediator of the ischaemic pre-conditioning 
phenomenon (reviewed in  [10] ). 
 HO-1 Upregulation as Therapy in Renal IRI 
 HO-1 gene transcription is influenced by pleiotropic 
signals including heme itself, heat shock, hypoxia (in part 
via stabilization of hypoxia-inducible factor-1  ), and in-
flammatory cytokines. These diverse stimuli act via a 
similarly broad range of signalling pathways. The pro-
moter region of HO-1 contains binding sites for nuclear 
factor (NF)-  B and activator protein-1 and 2, amongst 
others (comprehensively reviewed in  [11] ). The transcrip-
tion factor NF-E2-related factor-2 (Nrf2) is recognized as 
 Free heme
Free Fe2+ Biliverdin CO
Binding with ferritin  Bilirubin
Biliverdin reductase
Heme compounds
Secondary   
oxidative stress
Cell stress
IRI,
Toxins, etc.
 ROS,
  
Hemoglobin
iNOS
NADPH oxidase
Cyclooxygenase
Myoglobin
Cytochromes, etc.
+
+
–
HO-1
 Fig. 1. The heme-HO-1 pathway. ROS = Reactive oxygen species; 
iNOS = inducible nitric oxide synthase; NADPH = nicotinamide-
adenine dinucleotide phosphate reduced form. 
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the key mediator of HO-1 induction and protection seen 
after experimental IRI both in vivo and in vitro  [11, 12] , 
and is a focus of ongoing research. 
 Much of our understanding of the potential of HO-1 
as a therapeutic target in renal IRI came from studies ex-
amining whether the administration of pharmacological 
agents to either induce or inhibit HO-1 modulates the 
outcome of experimental renal IRI (reviewed in  [10] ). In 
general, chemically induced upregulation of HO-1 prior 
to the induction of IRI results in functional and struc-
tural protection, whilst the inhibition of HO-1 activity 
typically abolishes the protected phenotype and often 
augments injury. Such approaches are not without cave-
ats, as the widely used HO-1 inducer hemin is itself a pro-
oxidant whilst HO-1-inhibiting protoporphyrin com-
pounds almost ubiquitously inhibit the activity of other 
physiologically relevant enzymes, such as inducible nitric 
oxide synthase  [13] . 
 Putative Mechanisms Mediating HO-1 Protection
in IRI 
 Given that HO-1 activity results in the removal of a 
potent cell stressor and the production of biologically ac-
tive metabolites, the mechanisms underlying the protect-
ed phenotypes reproducibly seen following HO-1 induc-
tion are complex and likely multifactorial ( fig. 2 ). The de-
velopment of novel carbon monoxide-releasing molecules 
(CORMs) that act as CO donors in vivo will allow the 
relative contribution of the downstream products of HO 
activity (including HO-1) to be probed. Indeed, studies 
with pre-administration of CORMs have demonstrated 
functional protection comparable to HO-1 induction in 
IRI, implicating CO as a key component of the protected 
renal phenotype associated with HO-1 induction  [14]. 
 Effects on Renal Blood Flow and Microcirculation 
 Chemical inhibition of HO-2 and HO-1 activity in the 
healthy kidney results in reduced medullary blood flow, 
thus supporting a role for HO-1 in the maintenance of 
medullary perfusion under physiological conditions  [15] . 
The potential importance of induced HO-1 in maintain-
ing renal perfusion has been demonstrated by studies in-
volving the pre-treatment of donor rats with hemin to 
induce HO-1 expression. The subsequent transplants ex-
hibited preserved renal function, with an increase in cap-
illary blood flow and the diameter of intra-renal vessels 
by intravital microscopy  [16] . It is now recognized that 
CO exerts important effects on the circulation via its po-
tent vasodilatory effects and potentially via the inhibition 
of platelet aggregation  [17] . In explanted kidneys in an 
CD8+ regulatory T cell
HO-1
Biliverdin CO f Leukocyte 
recruitment
f Platelet
aggregation
f Leukocyte 
activation
Free radical
scavenging
Recruited
monocyte
Thrombus
Renal vasculature
Injured renal medulla
Renal leukocyte
Renal blood flow
Inhibition of apoptosis
+
+ +
−−
−
−
Heme
Fe2+
Fe2+ Ferritin
 Fig. 2. Current working hypothesis of the 
putative actions of  HO-1 in AKI. 
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isolated organ-perfusion circuit, CORM-derived CO had 
beneficial effects on renal blood flow and creatinine 
clearance. This is clearly independent of any effects on 
systemic haemodynamics, demonstrating the impor-
tance of the intra-renal actions of CO  [18] . Micropunc-
ture studies have demonstrated that HO-1 induction by 
stannous mesoporphyrin inhibits tubuloglomerular 
feedback-induced afferent arteriolar vasoconstriction 
 [19] . This effect is reproduced by the administration of 
either a CORM or exogenous biliverdin, thus implicating 
both heme metabolites in the mediation of this effect. 
Studies combining inhaled CO with infused bilirubin in 
rat renal transplantation demonstrated synergistic ef-
fects on both graft survival and on glomerular filtration 
rate and blood flow rates  [20] . 
 Effects on Cell Apoptosis and Survival 
 In keeping with the cytoprotective role of HO-1, there 
is a consistent pattern of reduced cell death present 
throughout studies of HO-1 upregulation whilst converse-
ly HO-1 inhibition or constitutive absence results in in-
creased levels of apoptosis and necrosis. The pleiotropic 
effects of HO-1 make dissection of the exact mechanism of 
this pro-survival effect problematic. Although it remains 
possible that it is a secondary phenomenon due to the im-
proved tissue perfusion and reduced immune cell activa-
tion, there is considerable evidence from other organs im-
plicating CO as an anti-apoptotic signal when present in 
physiologic concentrations  [21] . Additional in vitro evi-
dence from studies of cultured tubular epithelial cells has 
implicated HO-1 as promoting cell survival by induction 
of the cyclin-dependent kinase inhibitor p21  [22] .
 Modulation of Local or Systemic Immune Phenotype 
 The role of HO-1 in the modulation of immune re-
sponses is a rapidly evolving field in immunology, with 
an increasing recognition that HO-1 may act as a ‘mo-
lecular brake’ on the activation, recruitment and ampli-
fication of immune responses (reviewed in  [1] ). Overex-
pression of HO-1 results in reduced expression of endo-
thelial leukocyte adhesion molecules and reduced 
activity of the NF-  B pathway whilst constitutively HO-
1-deficient animals exhibit increased levels of monocyte 
chemoattractant protein-1  [5] . Constitutive HO-1 expres-
sion by the Kupffer cells of the liver has been demonstrat-
ed to be of benefit in hepatic IRI  [23] , and HO-1 is in-
duced within renal macrophages by statin therapy, an in-
tervention associated with a protected phenotype in IRI 
 [24] . Recently published work has implicated HO-1 as a 
target antigen for CD8+ regulatory T cells, resulting in 
profound immunomodulation of cellular immune re-
sponses  [25] . This finding reinforces results from HO-1-
null animals showing expanded regulatory T cell num-
bers, which fail to adopt a regulatory phenotype in vivo 
due to the absence of HO-1 within the antigen-presenting 
cell  [26] . Given the recognized role of lymphocyte popu-
lations in determining susceptibility to IRI, this adds an 
additional ‘extra-enzymatic’ arm to the immunomodula-
tory properties of HO-1.
 HO-1 – a Target for Translatable Therapies? 
 Understanding the mechanisms mediating the initia-
tion and propagation of renal IRI remains the focus of 
intense research worldwide. Despite this, the challenge 
remains to generate therapies that can be translated suc-
cessfully ‘from bench to bedside’ to improve outcome in 
what remains a devastating clinical problem. As with 
many agents showing therapeutic promise in animal 
studies, the utility of HO-1-based interventions are cur-
rently limited by the apparent need to administer therapy 
prior to the onset of the renal insult. 
 There are, however, a number of clinical settings such 
as major cardiac or vascular surgery and admissions into 
critical care environments where AKI may be probable, 
or in the case of renal transplantation, inevitable. Addi-
tionally, the advent of better identification of individuals 
at high risk of developing AKI or incipient AKI using cri-
teria such as RIFLE may allow windows of therapeutic 
opportunity to be identified to allow timely intervention. 
There is clearly a need for HO-1-inducing agents licensed 
for use in humans, or other novel interventions such as 
CORM administration or the inhalation of low-concen-
tration CO during ‘high-risk’ surgery. The documented 
HO-1-inducing effects of statins coupled to their estab-
lished safety profile make them intriguing candidates, al-
though it is of note that the multi-centre ALERT study 
looking at statin administration in transplantation 
showed no positive impact on acute or chronic rejection 
or graft function over 5+ years  [27] , in contrast to their 
promising immunomodulatory effects in experimental 
disease.
 Conclusions 
 The heme-HO-1 system appears of intrinsic impor-
tance in the evolution of AKI. Further elucidation of 
which aspects of the HO-1 pathway are indispensible to 
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renal protection will be necessary, potentially coupled to 
the generation of novel therapeutic molecules to harness 
such mechanisms and allow successful translation to the 
clinic.
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